Sagimet Biosciences Announces Oral Presentation at the MASH Pathogenesis and Therapeutic Approaches Keystone Symposium

Core Insights - Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics targeting metabolic and fibrotic pathways, with its lead drug candidate denifanstat showing promise in treating metabolic dysfunction associated steatohepatitis (MASH) [1][3] Company Overview - Sagimet is developing novel fatty acid synthase (FASN) inhibitors aimed at addressing diseases caused by the overproduction of palmitate [3] - Denifanstat is an oral, once-daily selective FASN inhibitor currently in development for MASH, having completed a successful Phase 2b clinical trial (FASCINATE-2) with positive results [3] - The FDA has granted Breakthrough Therapy designation to denifanstat for treating non-cirrhotic MASH with moderate to advanced liver fibrosis, supporting its advancement into Phase 3 development [3] Upcoming Presentation - An oral presentation on denifanstat's effects on triglycerides and LDL-cholesterol in advanced fibrosis patients will be delivered at the MASH Pathogenesis and Therapeutic Approaches Keystone Symposium on February 26, 2025 [1][2] - The presentation will include lipidomic data from a post-hoc analysis of the Phase 2b FASCINATE-2 trial [1][2] Industry Context - MASH is a severe liver disease affecting over 115 million people globally, with only one recently approved treatment in the U.S. and none in Europe [4] - The renaming of non-alcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated steatotic liver disease (MASLD) and nonalcoholic steatohepatitis (NASH) to MASH aims to improve diagnostic clarity and reduce stigma [4]